These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 19954406)

  • 21. Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers.
    Dhumal RS; Shimpi SL; Paradkar AR
    Acta Pharm; 2007 Sep; 57(3):287-300. PubMed ID: 17878109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Statistical evaluation of influence of polymers concentration on disintegration time and diazepam release from quick-disintegrating rapid release tablet.
    Giri TK; Sa B
    Yakugaku Zasshi; 2009 Sep; 129(9):1069-75. PubMed ID: 19721383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro controlled release of sodium ferulate from Compritol 888 ATO-based matrix tablets.
    Li FQ; Hu JH; Deng JX; Su H; Xu S; Liu JY
    Int J Pharm; 2006 Nov; 324(2):152-7. PubMed ID: 16837152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preparation of rapidly disintegrating tablets containing itraconazole solid dispersions.
    Oshima T; Sonoda R; Ohkuma M; Sunada H
    Chem Pharm Bull (Tokyo); 2007 Nov; 55(11):1557-62. PubMed ID: 17978511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fast dispersible/slow releasing ibuprofen tablets.
    Fini A; Bergamante V; Ceschel GC; Ronchi C; de Moraes CA
    Eur J Pharm Biopharm; 2008 May; 69(1):335-41. PubMed ID: 18182280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigation of some materials as dry binders for direct compression in tablet manufacture. Part 7: Formulation and evaluation of ascorbic acid and phenobarbitone tablets.
    Asker AF; Saied KM; Abdel-Khalek MM
    Pharmazie; 1975 Jul; 30(7):466-70. PubMed ID: 1178765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Studies on cyclodextrin polymer. Part 1: The effect of CDP on indomethacin tablet formulation.
    Tarimci N; Celebi N
    Pharmazie; 1988 May; 43(5):323-5. PubMed ID: 3174808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stabilization of the maleate salt of a basic drug by adjustment of microenvironmental pH in solid dosage form.
    Zannou EA; Ji Q; Joshi YM; Serajuddin AT
    Int J Pharm; 2007 Jun; 337(1-2):210-8. PubMed ID: 17296277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies.
    Fu Y; Yang S; Jeong SH; Kimura S; Park K
    Crit Rev Ther Drug Carrier Syst; 2004; 21(6):433-76. PubMed ID: 15658933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Taste masking microspheres for orally disintegrating tablets.
    Xu J; Bovet LL; Zhao K
    Int J Pharm; 2008 Jul; 359(1-2):63-9. PubMed ID: 18455893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets.
    Sheftell FD; Dahlöf CG; Brandes JL; Agosti R; Jones MW; Barrett PS
    Clin Ther; 2005 Apr; 27(4):407-17. PubMed ID: 15922814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The technologies used for developing orally disintegrating tablets: a review.
    Badgujar BP; Mundada AS
    Acta Pharm; 2011 Jun; 61(2):117-39. PubMed ID: 21684842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and evaluation of orally disintegrating tablets containing the mosapride resin complex.
    Wu T; Wang G; Shi C; Li J; Zhao N; Dong Z; Pan W; Zhang X
    Acta Pharm; 2018 Jun; 68(2):159-170. PubMed ID: 29702482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-amylose carboxymethyl starch matrices for oral sustained drug-release: in vitro and in vivo evaluation.
    Nabais T; Brouillet F; Kyriacos S; Mroueh M; Amores da Silva P; Bataille B; Chebli C; Cartilier L
    Eur J Pharm Biopharm; 2007 Mar; 65(3):371-8. PubMed ID: 17275270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro and in vivo evaluation of nimesulide lyophilized orally disintegrating tablets.
    Shoukri RA; Ahmed IS; Shamma RN
    Eur J Pharm Biopharm; 2009 Sep; 73(1):162-71. PubMed ID: 19406232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Preparation and quality control of pyridostigmine bromide orally disintegrating tablet].
    Zhang L; Tan QY; Cheng XG; Wang H; Hu NN; Zhang JQ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 May; 43(3):458-61, 477. PubMed ID: 22812258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Varying efficacy of superdisintegrants in orally disintegrating tablets among different manufacturers.
    Mittapalli RK; Qhattal HS; Lockman PR; Yamsani MR
    Pharmazie; 2010 Nov; 65(11):805-10. PubMed ID: 21155386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and optimization of a sublingual tablet formulation for physostigmine salicylate.
    Bolourchian N; Hadidi N; Foroutan SM; Shafaghi B
    Acta Pharm; 2009 Sep; 59(3):301-12. PubMed ID: 19819826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The application of solid dispersion technique in the preparation of therapeutic tablets. Part 1: Paracetamol, amylobarbitone, and caffeine tablets.
    El-Banna HM; Eshra AG; Hammouda Y
    Pharmazie; 1977; 32(8-9):511-5. PubMed ID: 145597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Solid dispersions based on inulin for the stabilisation and formulation of delta 9-tetrahydrocannabinol.
    van Drooge DJ; Hinrichs WL; Wegman KA; Visser MR; Eissens AC; Frijlink HW
    Eur J Pharm Sci; 2004 Mar; 21(4):511-8. PubMed ID: 14998582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.